bluebird bio, Inc. (NASDAQ:BLUE) Stake Decreased by Principal Financial Group Inc.

Principal Financial Group Inc. decreased its stake in bluebird bio, Inc. (NASDAQ:BLUE) by 0.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,425 shares of the biotechnology company’s stock after selling 74 shares during the period. Principal Financial Group Inc. owned approximately 0.05% of bluebird bio worth $2,038,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Martingale Asset Management L P increased its stake in bluebird bio by 0.6% in the first quarter. Martingale Asset Management L P now owns 17,008 shares of the biotechnology company’s stock valued at $1,547,000 after buying an additional 100 shares in the last quarter. First Mercantile Trust Co. increased its stake in shares of bluebird bio by 14.4% in the first quarter. First Mercantile Trust Co. now owns 2,897 shares of the biotechnology company’s stock worth $263,000 after buying an additional 365 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of bluebird bio by 0.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 68,220 shares of the biotechnology company’s stock worth $4,210,000 after buying an additional 540 shares during the period. Great West Life Assurance Co. Can increased its stake in shares of bluebird bio by 28.5% in the first quarter. Great West Life Assurance Co. Can now owns 4,509 shares of the biotechnology company’s stock worth $409,000 after buying an additional 1,000 shares during the period. Finally, Strs Ohio increased its stake in shares of bluebird bio by 40.5% in the first quarter. Strs Ohio now owns 5,900 shares of the biotechnology company’s stock worth $536,000 after buying an additional 1,700 shares during the period.

bluebird bio, Inc. (NASDAQ:BLUE) opened at 96.05 on Friday. bluebird bio, Inc. has a 12-month low of $37.05 and a 12-month high of $123.75. The stock’s 50 day moving average is $103.56 and its 200-day moving average is $87.10. The company’s market capitalization is $3.93 billion.

bluebird bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, May 3rd. The biotechnology company reported ($1.68) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.76) by $0.08. The company had revenue of $6.83 million during the quarter, compared to analysts’ expectations of $1.51 million. bluebird bio had a negative net margin of 2,402.03% and a negative return on equity of 35.17%. On average, equities analysts predict that bluebird bio, Inc. will post ($6.70) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “bluebird bio, Inc. (NASDAQ:BLUE) Stake Decreased by Principal Financial Group Inc.” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://sportsperspectives.com/2017/07/23/bluebird-bio-inc-nasdaqblue-stake-decreased-by-principal-financial-group-inc.html.

BLUE has been the subject of a number of research reports. BTIG Research reissued a “buy” rating on shares of bluebird bio in a report on Monday, May 1st. Cantor Fitzgerald set a $37.00 price target on shares of bluebird bio and gave the company a “sell” rating in a report on Monday, June 5th. Zacks Investment Research raised shares of bluebird bio from a “sell” rating to a “hold” rating in a report on Monday, May 8th. Maxim Group raised shares of bluebird bio from a “hold” rating to a “buy” rating and set a $100.00 price target for the company in a report on Friday, June 2nd. Finally, Bank of America Corporation reissued a “hold” rating and issued a $95.00 price target on shares of bluebird bio in a report on Monday, June 5th. Two analysts have rated the stock with a sell rating, six have given a hold rating and twelve have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $100.02.

In other news, Director Daniel Lynch sold 2,000 shares of the business’s stock in a transaction dated Tuesday, April 25th. The shares were sold at an average price of $86.75, for a total value of $173,500.00. Following the completion of the sale, the director now owns 3,400 shares of the company’s stock, valued at $294,950. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Philip D. Gregory sold 1,500 shares of the business’s stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $99.04, for a total transaction of $148,560.00. Following the completion of the sale, the insider now directly owns 37,279 shares of the company’s stock, valued at approximately $3,692,112.16. The disclosure for this sale can be found here. In the last three months, insiders sold 76,245 shares of company stock valued at $7,924,508. 3.90% of the stock is currently owned by company insiders.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply